Astraea

Agents that accelerate clinical trials.

Spring 2026ActiveB2BArtificial IntelligenceSaaSHealth TechSan Francisco, CA, USA

Company

Astraea automates clinical trial biometrics from raw study inputs to FDA-ready outputs. The platform handles data normalization, CDISC mapping, SDTM, ADaM, TFLs, QC, and revision workflows in one auditable system, helping Phase II/III sponsors reduce months of manual programming and data management into automated, reviewable execution.

Note: This is a preliminary assessment based on limited publicly available information. We did not have access to LinkedIn profiles or live product screenshots for this analysis. We will update this entry with a more thorough review soon.

Verdict

High Signal

Market Opportunity

Clinical trial biometrics (biostatistics, data management, regulatory submissions) is a massive, underserved B2B market. Phase II/III sponsors spend enormous sums on CROs and manual SAS/R programming for CDISC-compliant deliverables. The ICP is clear (pharma/biotech sponsors), the pain is acute and measurable (months of delays), and FDA regulatory requirements create durable demand. TAM easily exceeds $1B given global CRO market size.

Medium Signal

Founder Signal

Sanmay Sarada has a Data Engineer role at Baylor College of Medicine and 4 publications in Fetal Medicine, plus CS/Bio at Stanford — this is the most relevant signal for clinical trial biometrics. Joshua Wang is a Stanford CS/Math undergrad with USAMO/USACO credentials and an early internship at Salient (W23), but appears to be a recent or current grad with limited industry experience. The team has domain knowledge but no prior exits and limited real-world shipping history.

Medium Signal

Competition

Established players include Medidata (Veeva), Biovia, SAS-based CRO services, and niche tools like Pinnacle 21 for CDISC validation. No direct 'AI-native' competitor appears dominant yet. The incumbents are legacy and slow-moving, creating a window. However, large CROs (IQVIA, Covance, PPD) have internal tooling and entrenched relationships, making enterprise sales cycles long and trust-building critical.

Medium Signal

Product

The description is technically specific — CDISC mapping, SDTM, ADaM, TFLs, QC workflows — which suggests real domain knowledge and not just vaporware. However, no customer logos, no revenue metrics, no live demo or pricing page visible, and no press coverage. Landing page substance exists but no proof of paying customers.

OverallB Tier

Astraea is targeting a real, high-value pain point in clinical trial operations where manual CDISC programming genuinely costs sponsors months and millions. Sanmay's background at Baylor with publications in fetal medicine provides rare domain credibility for this regulatory-heavy space. The core risk is team maturity — Joshua appears to be a talented but early-career engineer, and there's no evidence of paying customers, prior exits, or enterprise traction yet. The market is strong and the technical specificity of the product description is encouraging, but this needs to prove it can navigate FDA-adjacent trust barriers and close pharma sponsors before it becomes a real contender.

Active Founders

Sanmay Sarada

Founder

prev Data Engineer @ Baylor College of Medicine | 4 Publications in Fetal Medicine | CS and Bio at Stanford

Joshua Wang

Founder

Previous undergraduate at Stanford studying CS and Math. Top 250 united states (USAMO) Qualifier, USACO Platinum, first intern at Salient (W23) developing enterprise systems.

Astraea

TierB Tier

BatchSpring 2026

Team Size2

StatusActive

LocationSan Francisco, CA, USA

Disagree with this rating? Let us know

$200 GPU creditsClaim yours →